Novo Nordisk has developed a new compound that combines GLP-1 and leptin to suppress appetite and aid weight loss in mice. This dual therapy approach may offer more effective treatment for obesity, with potential for human application.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing